NXTS vs AMGN Stock Comparison

Nexentis Technologies and Amgen Prices as of Oct 23, 2026 Peers: Industry group
AMGN Amgen Inc
$439.26 +8.2% 1M +50.0% 1Y
Market cap
$240.04B
P/E
27.5x
Revenue (TTM)
$38.10B
Div. yield
0.02%
Biotechnology Healthcare
5 wins

Head to Head

6 decided of 12

Amgen leads on 5 of the 12 questions below (Amgen 5, Nexentis Technologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSAMGNLeader
Larger companyMarket capitalisation $432.55K $240.04B AMGN
Cheaper on earningsLower P/E, profitable companies only 0.0x 27.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 20.1x –
Faster revenue growthRevenue growth, trailing twelve months — +9.1% –
More profitableNet margin, trailing twelve months — 23.0% –
Better return on capitalReturn on invested capital — 14.3% –
Less leveragedLower net debt / EBITDA 1.6x 2.7x NXTS
Higher dividend yieldTrailing dividend yield 0.00% 0.02% –
Better 1-year returnPrice return, last 12 months -98.1% +50.0% AMGN
Better 5-year returnAnnualised price return, 5 years -86.3%/yr +16.0%/yr AMGN
Less volatileAnnualised volatility, 1 year 168.8% 29.6% AMGN
Higher overall scoreMean of the five percentile scores vs peers 32/100 66/100 AMGN

Percentile Scorecard

NXTSAMGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSAMGN
Valuation – 85 #92 of 624
Growth 13 #526 of 603 62 #231 of 603
Profitability 40 #334 of 555 94 #32 of 555
Financial Health 43 #373 of 657 22 #512 of 657
Shareholder Returns – 68 #118 of 370
Overall 32 66
  • NXTS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • AMGN ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSAMGNSPY
1 month -63.7%+8.2% -1.0%
3 months -70.6%+16.8% +2.9%
6 months -89.4%+27.5% +6.4%
Year to date -95.5%+34.2% +11.4%
1 year -98.1%+50.0% +13.1%
3 years -99.9%+59.1% +79.4%
3 years, per year -90.0%+16.7% +21.5%
5 years -100.0%+109.9% +67.7%
5 years, per year -86.3%+16.0% +10.9%
10 years -100.0%+177.1% +255.2%
10 years, per year -66.8%+10.7% +13.5%

Risk

MeasureNXTSAMGNSPY
Volatility, 1Y 168.8%29.6% 12.7%
Downside volatility, 1Y 152.8%27.6% 12.7%
Beta vs S&P 500, 1Y 2.240.44 1.00
Return / volatility, 1Y -0.581.69 1.03
Max drawdown, 5Y -100.0%-26.7% -25.4%
From 52-week high -98.1%-1.8% -2.5%
52-week high $28.63$447.28 $779.14
52-week low $0.53$291.16 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSAMGN
P/E now vs peer median 0.0xmedian 17.2x 27.1xmedian 17.2x
P/S now vs peer median —median 8.8x 6.2xmedian 8.8x
EV/EBITDA now vs peer median 1.5xmedian 16.0x 17.4xmedian 16.0x
P/FCF now vs peer median —median 17.8x 23.3xmedian 17.8x
P/B now vs peer median 0.2xmedian 2.1x 20.3xmedian 2.1x
PEG now vs peer median 0.00median 0.32 10.23median 0.32

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSAMGN
Revenue – $38.10B
Gross profit – $26.48B
Operating income -$5.28M $11.43B
Net income -$14.06M $8.74B
Free cash flow – $10.18B
R&D $532.00K $7.63B
EPS (diluted) $-17.10 $16.07
Cash & equivalents $7.62M $13.99B
Total debt $3.22M $57.30B
Shares (diluted) 816.14K 544.00M
Enterprise value -$22.21M $195.44B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSAMGN
P/E 0.0x 27.1x
P/FCF – 23.3x
P/Operating cash flow – 19.0x
P/S – 6.2x
P/B 0.2x 20.3x
P/Tangible book -0.2x -27.0x
EV/EBITDA 1.5x 17.4x
EV/EBIT 1.5x 24.6x
EV/Revenue – 7.4x
EV/FCF – 27.6x
EV/Operating cash flow – 22.5x
PEG (3Y EPS CAGR) 0.00 10.23

Growth

14 metrics
MetricNXTSAMGN
Revenue growth (1Y) – 9.1%
Revenue CAGR (3Y) – 12.7%
Gross profit growth (1Y) – 17.6%
Gross profit CAGR (3Y) – 10.3%
Operating income growth (1Y) -7.7% 39.5%
Operating income CAGR (3Y) 3.0% 6.4%
Net income growth (1Y) -48.2% 32.1%
Net income CAGR (3Y) -35.8% 3.1%
EPS growth (1Y) -567.8% 31.4%
EPS CAGR (3Y) -45.2% 2.7%
Operating cash flow growth (1Y) – 3.9%
Operating cash flow CAGR (3Y) – 4.9%
Free cash flow growth (1Y) – -4.1%
Free cash flow CAGR (3Y) – 1.7%

Profitability

14 metrics
MetricNXTSAMGN
Gross margin – 69.5%
EBITDA margin – 42.2%
Operating margin – 30.0%
Pretax margin – 27.0%
Net margin – 23.0%
FCF margin – 26.7%
Operating cash flow margin – 32.8%
Return on equity -157.0% 83.8%
Return on assets -71.9% 9.3%
Return on invested capital – 14.3%
Return on capital employed -31.5% 16.7%
Asset turnover – 0.4x
Cash conversion (OCF / net income) – 1.4x
Stock comp / revenue – 1.3%

Financial Health

11 metrics
MetricNXTSAMGN
Debt / assets 2.3% 59.9%
Debt / equity 0.2x 4.9x
Net debt / EBITDA 1.6x 2.7x
Debt / FCF – 5.6x
Liabilities / assets 89.8% 87.8%
Equity / assets 10.2% 12.2%
Interest coverage – 4.3x
Current ratio 3.7x 1.4x
Quick ratio 3.2x 0.9x
Cash ratio 3.2x 0.5x
Altman Z-score – 2.28

Shareholder Returns

7 metrics
MetricNXTSAMGN
Dividend yield – 2.3%
Net buyback yield – –
Shareholder yield – 2.3%
Payout ratio (earnings) – 60.4%
Payout ratio (FCF) – 51.9%
Dividend growth (1Y) – 6.3%
Dividend CAGR (3Y) – 6.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSAMGN
Forward P/E – 20.1xFY2026
EPS, next fiscal year – $21.80FY2026
EPS growth, next FY – -0.2%FY2026
EPS growth, the year after – +7.3%
Revenue, next fiscal year – $41.51BFY2026
Revenue growth, next FY – +12.9%FY2026
Revenue growth, the year after – +2.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSAMGN
Held by institutions – 82.7%
Institutions holding – 3,159
Change in shares held, QoQ – +4.5%
Institutions buying – 1,451
Institutions selling – 1,217
Buyers to sellers – 1.19

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSAMGN
NXTS 1.00 0.02
AMGN 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS and AMGN?

Amgen (AMGN) is the largest by market capitalisation: Nexentis Technologies (NXTS) $432.55K, Amgen (AMGN) $240.04B.

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Nexentis Technologies (NXTS) -98.1%, Amgen (AMGN) +50.0%. Over five years, Amgen (AMGN) compounded fastest (Nexentis Technologies (NXTS) -86.3%/yr, Amgen (AMGN) +16.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Nexentis Technologies (NXTS) 0.00%, Amgen (AMGN) 0.02%. Nexentis Technologies (NXTS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Nexentis Technologies (NXTS) 168.8%, Amgen (AMGN) 29.6%). Volatility measures how widely the price swings, not the risk of the business.

Do NXTS and AMGN move together?

Their daily returns over the past year have a correlation of 0.02, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, NXTS and AMGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.